A5041925942- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Immunodeficiency and Autoimmune Disorders
- COVID-19 and healthcare impacts
- Acute Myeloid Leukemia Research
- COVID-19 Clinical Research Studies
- Acute Lymphoblastic Leukemia research
- Vascular anomalies and interventions
- Venous Thromboembolism Diagnosis and Management
- Bartonella species infections research
- CAR-T cell therapy research
- Neutropenia and Cancer Infections
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Renal and related cancers
- CNS Lymphoma Diagnosis and Treatment
- Lymphadenopathy Diagnosis and Analysis
- Galectins and Cancer Biology
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Central Venous Catheters and Hemodialysis
- Economic and Financial Impacts of Cancer
- Blood Coagulation and Thrombosis Mechanisms
- Ovarian cancer diagnosis and treatment
- Pneumocystis jirovecii pneumonia detection and treatment
Hospital Universitario Infanta Leonor
2015-2025
Memorial Sloan Kettering Cancer Center
2023
Hospital General Universitario Gregorio Marañón
2012
Summary The diagnostic criteria for follicular lymphoma ( FL ) transformation vary among the largest series, which commonly exclude histologically‐documented HT mandatorily. aims of this retrospective observational multicentre study by Spanish Grupo Español de Linfoma y Transplante Autólogo Médula Ósea, recruited 1734 patients (800 males/934 females; median age 59 years), diagnosed with grades 1–3A, were, (i) cumulative incidence CI ‐ ); (ii) risk factors associated ; and (iii) role...
Relapse remains the main cause of treatment failure in patients with acute myelogeous leukemia (AML) after allogeneic hemopoietic stem cell transplantation (SCT). The Wilms' tumor 1 gene (WT1) is reportedly overexpressed >90% AML and thus can be useful for minimal residual disease (MRD) monitoring. aim this study was to evaluate usefulness WT1 expression as a relapse predictor marker SCT compare it flow cytometry (FC) chimerism studies. assessed retrospectively using quantitative RT-PCR bone...
Background/Objectives: Brentuximab vedotin (BV) has been shown to be effective in the treatment of classical Hodgkin’s lymphoma (cHL), systemic anaplastic large cell (sALCL), and CD30-positive cutaneous T-cell (CTCL). This study aimed evaluate effectiveness safety BV retreatment patients with relapsed/refractory cHL, sALCL, CTCL. Methods: multicenter, non-interventional, retrospective medical chart review analyzed records from 43 retreated Spain. Patients were included if they had relapsed...
International Journal of Laboratory HematologyVolume 42, Issue 6 p. e256-e259 LETTER TO THE EDITOR COVID-19 in patients with hematological malignancies: A retrospective case series Maria-Stefania Infante, Corresponding Author Infante [email protected] orcid.org/0000-0003-0096-9359 Hematology Department, University Hospital Infanta Leonor, Madrid, Spain Correspondence Maria Stefania Universitario C/ Gran Vía del Este 80, Madrid 28031, Spain. Email: protected]Search for more papers by this...
In recent years, new prognostic indexes (PIs) for chronic lymphocytic leukemia (CLL), which include clinical, biological, and genetic variables, have been validated, highlighting the MD Anderson Cancer Center index (MDACC PI), CLL-international (CLL-IPI), Barcelona-Brno biomarkers only model. The aim of this study is to compare utility these PIs in a cohort Spanish patients. A retrospective analysis 696 unselected CLL patients newly diagnosed previously untreated from different institutions...
Abstract Background Lymphoid neoplasms treatment has recently been renewed to increase antitumor efficacy and conventional chemotherapies toxicities. Limited data have published about the infection risk associated with these new drugs, therefore this study analyzes infectious complications in patients lymphoproliferative diseases (LPD) treated monoclonal antibodies (obinutuzumab, ofatumumab, brentuximab, nivolumab, or pembrolizumab), BTK inhibitors (ibrutinib acalabrutinib), PI3K...
Vaccine-associated hypermetabolic lymphadenopathy (VAHL) has been reported as a common post-vaccination side effect, especially with mRNA-based COVID-19 vaccines. Most VAHL cases present normal or enlarged regional lymph nodes close to the injection site, usually mild-moderate FDG (18 F-Fluorodeoxyglucose) uptake on positron emission tomography (PET)/CT. Here, we describe case of 33-year-old woman past history Classic Hodgkin Lymphoma (CHL) who underwent follow-up PET/CT 3 days (d) after...
Atresia of inferior vena cava (IVC) is a rare congenital malformation associated with high risk venous thrombosis that still has unknown etiology, although intrauterine IVC been suggested to be involved. The identification atresia in case early idiopathic and antithrombin deficiency caused by the homozygous SERPINC1 c.391C > T variant (p.Leu131Phe; Budapest 3) encouraged us evaluate role this severe thrombophilia vascular abnormality. We have done cross-sectional study previously identified...
Abstract Immunoglobulin heavy chain variable (IGHV) region mutations, TP53 mutation, fluorescence in situ hybridization (FISH), and cytogenetic analysis are the most important prognostic biomarkers used chronic lymphocytic leukemia (CLL) patients our daily practice. In real-life environment, there scarce studies that analyze correlation of these factors with outcome, mainly referred to time first treatment (TTFT) overall survival (OS). This study aimed typify IGHV mutation status, family...
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) R-bendamustine (R-B) are the most common frontline treatment strategies for advanced-stage follicular lymphoma (FL). After R-CHOP induction therapy, using rituximab maintenance therapy notably improves outcomes; however, whether this can be achieved by same approach after R-B is still being determined. This retrospective analysis compared 476 FL patients from 17 GELTAMO centers who received R-based regimens...
We analyzed the features of chronic lymphocytic leukemia (CLL) with multiple abnormalities (MA) detected by FISH. A local database including 2095 CLL cases was used and 323 MA (15.4%) were selected. defined presence two or more alterations (deletions 13q14 (13q-), 11q22 (11q-), 17p13 (17p-) trisomy 12 (+12)). The combination 13q- 11q- 17p-, accounted for 58.2% series, in contrast to 17p- (3.7%). Patients carrying since diagnosis presented a short time first therapy(TTFT) (27 months) overall...
Introduction: COVID-19 is thought to be more frequent and severe in patients with cancer. Lymphoma may especially vulnerable, due the immunodeficiency immune dysregulation caused by lymphoma itself antitumor treatments. This study describes characteristics outcomes of after developing COVID-19. Methods: a retrospective multicentre carried out hospitals GELTAMO group, which included histological diagnosis confirmed SARS-COV-2 infection before June 30th, 2020. The primary outcome was overall...
Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: WHO classification distinguishes two types of EATL: type 1 EATL (most frequent, 80-90%) is strongly associated with celiac disease (CD) and the majority cells express CD30; II EATL, monomorphic form a distinct immunophenotype (CD3+CD4-CD8+CD56+). In both types, TCRgamma genes are often clonally rearranged. The high mortality not only very aggressive chemotherapy-refractory nature lymphoma, but also prolonged severe...
Background: MM affects mainly patients older than 65 years. These are at higher risk for venous thromboembolism (VTE) because of cancer status, intrinsic factors and exposure to prothrombotic therapies. The VTE appears during the first months treatment (3‐4%). Exposure immunomodulatory drugs (IMDs) such as Lenalidomide Thalidomide in association with high dose dexametasone (HD‐DXM) or anthracyclin‐based chemotherapy is associated increased (26%). There recommendations available guide use...
Introduction: Extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKTL-NT) is a rare and aggressive disease associated with Epstein-Barr virus (EBV) infection. It much more common in Asia Latin America, data from European cases are very limited. Oncogenic alterations have not been fully described due to its rarity the difficulties inherent tumor high necrosis minimum-size biopsies. Treatment for ENKTL-NT lymphoma mainly based on cytotoxic therapy, little contribution of targeted...